Clinical trial NCT01287520 (phase 1, status: completed)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: ly2090314, pemetrexed, carboplatin
SMILES: FC1=CC2=C3N(CCN(C2)C(=O)N2CCCCC2)C=C(C3=C1)C1=C(C(=O)NC1=O)C1=CN=C2C=CC=CN12, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a performance status of less than or equal to 2 on the Eastern Cooperative
             Oncology Group (ECOG) scale

          -  Have a life expectancy of greater than or equal to 12 weeks

          -  Males and females with reproductive potential agree to use medically approved
             contraceptive precautions during the trial and for 3 months following the last dose of
             study drug

          -  Have histological or cytological evidence of a diagnosis of cancer that is advanced
             and/or metastatic disease for which no proven effective therapy exists

          -  Have the presence of measurable or nonmeasurable disease as defined by the Response
             Evaluation Criteria in Solid Tumors (RECIST)

          -  Have adequate hematologic, hepatic, and renal function

          -  Have discontinued all previous therapies for cancer, including chemotherapy,
             radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at
             least 30 days (6 weeks for mitomycin-C or nitrosoureas) prior to study enrollment and
             recovered from the acute effects of therapy.

        Exclusion Criteria:

          -  Have received treatment within 30 days of the initial dose of study drug with a drug
             that has not received regulatory approval for any indication

          -  Have serious preexisting medical conditions (left to discretion of investigator)

          -  Have one of the following conduction abnormalities: Corrected time between start of Q
             wave and end of T wave (QTc) prolongation >450 millisecond (msec) on screening
             electrocardiogram (ECG), previous history of QTc prolongation with another medication
             that required discontinuation, congenital long-QT-syndrome, or left bundle branch
             block (LBBB)

          -  Are taking any concomitant medication that may cause QTc prolongation, or induce
             Torsades de Pointes

          -  Have systolic blood pressure greater than or equal to 140 millimeters of Mercury (mm
             Hg), and diastolic blood pressure greater than or equal to 90 mm Hg that is not
             controlled by medical therapy

          -  Have serious cardiac condition, such as myocardial infarction within 6 months, angina,
             or heart disease, as defined by the New York Heart Association Class II or higher;
             have history of arrhythmia that is symptomatic or requires treatment

          -  Have chronic atrial fibrillation and/or bradycardia

          -  Have uncorrected electrolyte disorders including potassium <3.4 molar equivalent per
             liter (mEq/L) (<3.4 millimole per liter [mmol/l]), calcium <8.4 milligram per
             deciliter (mg/dL) (2.1 mmol/L), or magnesium <1.2 mg/dL (<0.62 mmol/L)

          -  Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not
             required)

          -  Have a hematologic malignancy

          -  Females who are pregnant or lactating